This work distinguished P2Y13-R as a new gatekeeper of the nuclear alarmins IL-33 and HMGB1 and recognized that targeting this GPCR via genetic deletion or therapy with a small-molecule antagonist defended against the onset and exacerbation of experimental asthma. This evidence concerns the gene IL33 and asthma.